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49,9%, lipid–lowering 22,7% and Antidiabetics the 6,1% of the total annual follow 
up medication cost . For the patients were subjected to ICD initial implantation 
antiplatelet–anticoagulants represent 24,4 %, antiarrhythmic 2,2 %, cardiovascular 
44,2 %, lipid–lowering 25,0% and antidiabetics 4,1% of the total annual follow up 
medication cost. For the patients were subjected to ICD replacement antiplate-
let–anticoagulants represent the 28,7 %, antiarrhythmic the 7,7 %, Cardiovascular 
58,1 %, Lipid–lowering 5,5% and Antidiabetics 0,0% of the total annual follow up 
medication cost . ConClusions: The present study provides unique data regard-
ing the percentage of annual medication cost attributed to each kind of treatment 
of unselected patients subjected to CRMDs implantation in a real-world setting.
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objeCtives: To estimate the cost-effectiveness of strategies for treatment deep 
vein thrombosis (DVT), the primary objective was to compare of effects of catheter-
directed thrombolysis (CDT) and anticoagulation versus anticoagulation in the man-
agement of people with DVT of the lower limb. DVT occurs when a blood clot forms 
in a leg vein. The clot can break up and move to the lungs, leading to a potentially 
serious blockage in blood flow (pulmonary embolism). Because of the damage to 
the leg vein, post-thrombotic syndrome (PTS) may develop any time over the next 
couple of years. Methods: We used a Markov state transition decision model to 
evaluate the cost-effectiveness of treatment strategies using a societal perspective 
for costs, effectiveness-measured in incremental cost-effectiveness. Data sources 
included the English language literature using MEDLINE searches and bibliographies 
from selected articles. Results: Our study showed that CDT may have advan-
tages over standard anticoagulation treatment. CDT effectively dissolved the clot 
so that complete clot breakdown occurred more often with CDT than with standard 
anticoagulant therapy. CDT and anticoagulation with compression stockings was 
associated with an effectiveness of 21.67 QALYs and a lifetime cost of $48 442. The 
incremental cost-effectiveness ratio (ICER) was $14 728/QALY gained. CDT increases 
the patency of veins and reduces the incidence of PTS following DVT by 35%. Strict 
eligibility criteria are necessary to reduce the risk of bleeding complications and this 
limits the applicability of this treatment. ConClusions: CDT and anticoagulation 
are highly cost-effective strategies for treatment patients with DVT and a low risk of 
bleeding. Use of strict eligibility criteria has improved the safety and acceptability 
of this treatment, with treatment directed by catheter in more extensive clots now 
the favoured method.
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objeCtives: To evaluate the economic value of dabigatran in the treatment of 
deep vein thrombosis (DVT), pulmonary embolism (PE) and prevention of recur-
rent events in comparison with other reimbursed oral anticoagulants warfarin 
and rivaroxaban from a perspective of Mexican public institutions. Methods: A 
Markov disease model with one month cycles length was developed. A number 
of parameters were followed in the model within the lifetime horizon (mean 18.2 
years from diagnosis for Mexican patients), including efficacy and safety relevant 
events and treatment related costs. Main modelling outcome was life-years gained. 
Identical hypothetical cohorts of patients entered the model, following either 
acute index DVT or PE (500 simulations per treatment arm). Modelled efficacy 
endpoints (recurrent venous thromboembolic events, including DVT, fatal and 
non-fatal PE), safety endpoints (major and clinically relevant non-major bleeds) 
and treatment related adverse events were utilized from published results of head 
to head clinical trials or derived in network meta-analysis and indirect compari-
sons. Public institutional direct medical costs (2014 purchases and price tabulators) 
where retrieved to adopt the national health system perspective. Results: Mean 
life-years saved for dabigatran, warfarin and rivaroxaban were 4.478, 4.475 and 
4.476 respectively. The highest cost of treatment was reported by rivaroxaban with 
7,959.15 USD, followed by warfarin (7,923.31 USD) and dabigatran (7,748.46 USD). 
ICER showed dabigatran is a dominant alternative versus both rivaroxaban and 
warfarin. Results were robust to changes in discount rates. Dabigatran remained 
as a dominant alternative versus rivaroxaban and as a cost-effective one ver-
sus warfarin, in a price sensitivity analysis. ConClusions: From a perspective 
of Mexican public institutions, the treatment with dabigatran resulted to be a 
cost-saving alternative that could potentially increase life-years gained without 
increasing health care spends.
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objeCtives: Atrial fibrillation (AF) is the most common cardiac rhythm disorder; it 
increases stroke risk 5 to 6 times. Prevalence in Colombia has been estimated in 3.6% 
in population age 60 or over (some 180 000 potential patients). The aim of this study 
was to estimate cost-effectiveness of dabigatran 110 mg and 150 mg BID as a therapy 
for non valvular AF in Colombian population. Methods: From a third-party payer 
perspective (Colombian health system) we used a three-month cycle Markov model 
with six health states (and death): non-disabling stroke, disabling stroke, acute myo-
cardial infarction and pulmonary embolism; two additional events were transient 
states: minor and mayor bleeding. Transition probabilities and proportion of events 
without CVEs for up to 3 years post-CVE, imposing a significant economic burden 
on U.S. commercial payers.
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objeCtives: Previous studies estimate that up to 15% of patients who undergo 
cardiovascular surgery require reoperation due to bleeding. The objective of this 
study is to estimate the incremental cost to hospitals for reoperations where a 
bleeding event is the primary reason across cardiovascular reconstructive surger-
ies. Methods: The study identified patients age 18 years or older with a record in 
the Premier hospital database between January 1, 2010 to September 30, 2012 who 
underwent cardiovascular reconstructive surgery. An algorithm (clinician expert 
rules and Premier Chargemaster data) was developed to define a reoperation where 
a bleeding event is the primary reason. Patients were excluded from analysis if 
extracorporeal circulation was utilized during the reoperation. The final sample 
included 294,548 patients in seven procedure groups: CABG, valve repair/replace-
ment, AAA repair, AV access, endarterectomy, femoral-femoral/femoral-popliteal 
bypass, and other vascular. Multivariable modeling was performed to estimate the 
incremental effect on hospital costs for bleeding events that required reoperation. 
Regression models to control for age, gender, race, marital status, insurance type, 
and severity and mortality risk were performed for each category of cardiac and 
vascular reconstructive surgery. Results: Descriptive results indicated that aver-
age hospital visit costs with no reoperation ranged between $10,832 [SD $10,731] 
and $48,768 [$28,368] depending on the procedure. The incremental additional cost 
per visit associated with a reoperation surgery for bleeding is estimated as follows 
by procedure group: CABG $30,951[$1,431]; valve repair $27,037 [$2,124]; AAA repair 
$30,145 [$1,235]; AV access $11,996 [$1,073]; endarterectomy $18,645 [$512]; fem-fem/
fem-pop bypass $44,383 [$1,699], and other vascular $25,861 [$432]. ConClusions: 
The incremental cost of reoperations for bleeding events in cardiac and vascular 
reconstructive surgery varied between 63% and 179% depending on the procedure 
group, with the largest increase for femoral-femoral bypass procedures, CABG, AAA 
repair, and valve procedures respectively.
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objeCtives: The objective of this investigation was to compare the contrasting 
results of recent cost-effectiveness analyses of statins. Methods: A systematic 
review of the literature on statin cost-effectiveness was conducted as per Cochrane 
methodology. Results: The four studies that met inclusion criteria reported vari-
able conclusions about the cost-effectiveness of statin treatment, without a clear 
unanimity as to whether statins are cost-effective for primary prevention. All stud-
ies analyzed health care costs from the health care system perspective – inclusive of 
and limited to all direct medical costs to all payers resulting from the statin therapy. 
The time horizon varied from as 5 years to lifetime. Annual drug prices ranged 
from $770 to over $1,500 in 2006 dollars. The studies reported varying assessments 
of the cost-effectiveness of statins. Costs ranged from $590,000 to $3 to extend 
life by one year. Recently published studies found statin therapy more likely to be 
cost-effective. However, when each study’s assumptions about statin costs were 
accounted, a substantial agreement among the authors was observed. Studies 
which assumed statins to be more costly found them to be less cost-effective, and 
vice-versa. Moreover, treatment of the lower risk groups appeared cost-effective as 
statins became cheaper. The studies were appraised using Philips and NICE checklist 
(qualitatively) and Quality of health economic studies (quantitatively). The studies 
were found to be of average quality. ConClusions: As the statins become generic, 
the chances of the patients at low risk for coronary disease may be treated cost-
effectively increases. It would be thus reasonable for clinicians to treat low-risk 
patients and statin therapy for a broader patient base, based on cost-effectiveness.
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objeCtives: To estimate the percentage of annual follow up medication cost attrib-
uted to each kind of treatment of unselected patients subjected to CRMDs implan-
tation in a real-world setting. Methods: During a period of one year in total 464 
(370 were subjected to PM implantation, 240 initial, 130 replacement and 94 to ICD 
implantation, 80 initial, 14 replacement) consecutive recipients were subjected to 
CRMD’s implantation and furthermore were recruited and followed up for 1 year. At 
six and twelve months after the procedure of implantation we record the medica-
tion use for each patient. Results: For the patients were subjected in PM initial 
implantation antiplatelet–anticoagulants represent 24,5%, antiarrhythmic 1,1,%, 
cardiovascular 47,8%, lipid–lowering 22,6% and antidiabetics 3,9% of the total annual 
follow up medication cost. For the patients were subjected to PM replacement anti-
platelet–anticoagulants represent 19,6%%, antiarrhythmic 1,7%, cardiovascular 
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objeCtives: To explore the cost-effectiveness of clopidogrel as secondary preven-
tion in patients with a recent ischemic stroke (IS), or established peripheral arte-
rial disease (PAD) compared with aspirin in China. Methods: A discrete event 
simulation was developed to evaluate the economic implications of secondary 
prevention with clopidogrel or aspirin, which are indicated for a patient with a 
recent MI, recent IS or established PAD. All available evidences were derived from 
clinical studies. Costs from Chinese health care perspective in 2013 US dollars 
and quality-adjusted life years (QALYs) were projected over a patient’s lifetime. 
Uncertainties were addressed using sensitivity analyses. Results: Compared with 
aspirin, clopidogrel yielded marginal life expectancy by 0.46 and 0.21 QALYs at 
an incremental cost-effectiveness ratio of $5,246 and $9,890 per QALY in patients 
with a recent IS and PAD, respectively. One-way sensitivity analyses showed evalu-
ation for patients with PAD and a recent IS was robust except the parameter of 
patient age. For the willingness to pay for $19,877 per QALY gained, clopidogrel 
intervention had a probability of 90% and 68% of being cost-effective for IS and 
PAD subgroups in comparison with aspirin, respectively. ConClusions: The 
analysis suggests that clopidogrel for the secondary prevention is cost effective for 
patients with either PAD or a recent IS in the Chinese setting in comparison with 
aspirin.
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objeCtives: Riociguat is the first product proven to improve health status in CTEPH 
patients. The objective of this study is to evaluate the cost-effectiveness of riociguat 
for patients with inoperable CTEPH or post-operative recurrent/persistent CTEPH in 
Turkey. Methods: A Markov model taking transitions of patients between func-
tional classes and death state as core was adapted to Turkish setting. Turkish payer’s 
perspective was taken and time-horizon was set as patient’s lifetime (maximum 30 
years) broken into four-month cycles. Riociguat was compared to placebo and com-
mon off-label treatments within the model. Essential clinical inputs were derived 
from CHEST-1 and CHEST-2 trials and local resource-utilization data were conducted 
through an expert panel. The incremental cost-effectiveness ratios (ICER) were calcu-
lated per life-years (LYs) gained and sensitivity of the results was analyzed for all com-
parators and placebo in terms of key inputs. All costs were calculated in Turkish Liras 
(TL) and converted to USD using TL/USD currency rate as 2.1 (mid-2014). Results: 
Total cost of riociguat-treated patients is 1,558, 7,342 and 59,706 USD higher compared 
to bosentan, ambrisentan and sildenafil respectively and 74,227 USD lower compared 
to iloprost. Besides, riociguat is associated with increments of 1.0034, 1.0878, 1.8174 
and 1.8872 LYs compared to bosentan, ambrisentan, iloprost, sildenafil and placebo 
respectively. The ICER of riociguat per LYs gained compared to bosentan, ambrisentan, 
sildenafil and placebo were determined as 1,553 USD, 6,750 USD, 31,638 USD and 
39,553 USD correspondingly. Model is sensitive only to the changes in “the starting 
age of the disease”, yet not to an extent to affect the final results. ConClusions: 
Riociguat is cost-effective for CTEPH treatment compared to bosentan, ambrisen-
tan, sildenafil and placebo with ICER values below the willingness-to-pay thresh-
old (3-times GDP per capita ─ 32,346 USD) for Turkey. Furthermore, riociguat is 
pharmacoeconomically dominant to iloprost with lower costs and higher clinical 
effectiveness.
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objeCtives: The objective of this study was to compare the efficacy, complica-
tions, and costs associated with urokinase versus alteplase for the catheter-directed 
treatment of acute peripheral artery disease (APAD). Methods: The cost-effec-
tiveness of catheter directed thrombolysis (CDT) with urokinase and alteplase for 
the treatment of APAD was compared using decision analysis. A literature-based 
decision model to evaluate cost-effectiveness was constructed. Successful treat-
ment outcomes were defined as clot lysis with a subsequent 30-day survival post-
treatment. Direct medical costs were assessed from the payer perspective in the 
Kazakhstan and analyzed using sensitivity analyses. A Monte Carlo analysis with 
1000 patients was performed to obtain mean and incremental cost-effectiveness 
ratios (ICERs). Results: The mean cost-effectiveness ratio was $148 463 per treat-
ment success for CDT with urokinase and $220 052 for CDT with alteplase. The ICER 
for alteplase relative to urokinase was $211 573 per additional CDT treatment suc-
cess. Approximately 75% of simulated cases indicated that alteplase was associated 
with increased costs and increased treatment success compared with urokinase. 
Also, when using alteplase higher risk of bleeding than with urokinase, this com-
plication is a major factor limiting the using of CDT. Results of a post hoc sensitivity 
analysis indicated that dominance decreased to approximately 10% of cases only 
under the most strict criteria. ConClusions: Decision analysis found an ICER of 
$211 573 per additional CDT treatment success for alteplase relative to urokinase in 
the treatment of APAD from the perspective of the payer in the Kazakhstan. In about 
75% of cases resulting from a Monte Carlo simulation, alteplase was associated 
with increased costs and slightly increased CDT treatment success compared with 
urokinase, although this finding was sensitive to the distributional assumptions 
made concerning certain costs in the model.
were extracted from the RELY trial; utilities were derived from the literature. Costs 
for medications and procedures were obtained from official government databases, 
all costs were in 2014 Colombian pesos (1 USD = 2000.33 COP). Annual discount 
rate was 5% and we used a life time horizon (close to 20 years, on average). Cost-
effectiveness threshold was 3 times per capita GDP (around USD 22,500). Results: 
Compared with warfarin, patients treated with dabigatran 150 and 110 mg gained, 
on average 0.37 and 0.23 life-years, respectively, or 0.38 and 0.25 QALYs. The ICER for 
dabigatran 150 mg was USD 13,248 per QALY, and for dabigatran 110 mg was 23,621 
per QALY. ConClusions: Dabigatran 150, compared with warfarin, the standard 
therapy, is cost-effective for ambulatory treatment of patients with non valvular AF. 
Dabigatran 110 ICER is discretely over the threshold (around 1000 USD).
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objeCtives: To determine the economic value of dabigatran for stroke preven-
tion in atrial fibrillation (SPAF) compared to other reimbursed oral anticoagulants 
warfarin, rivaroxaban and apixaban from a perspective of Mexican public institu-
tions. Methods: A Markov disease model with three month cycles length was 
developed. A number of clinically relevant events, including acute thromboembolic 
and bleeding events, as well as long-term consequences such as stroke, intracranial 
hemorrhage and acute myocardial infarction, were followed in the model within 
the lifetime horizon (mean 10 years from diagnosis for Mexican patients). Identical 
hypothetical cohorts of patients entered the model, following a disease background 
of atrial fibrillation (2500 simulations per treatment arm). Published results of head 
to head clinical trials or relative efficacy derived in network meta-analysis and indi-
rect comparisons were used to populate the model. Public institutional direct medi-
cal costs (2014 purchases and price tabulators) where retrieved to adopt the national 
health system perspective. Model outputs included total costs, event rates and 
life-years gained. Results: Mean life-years saved for dabigatran, apixaban, rivar-
oxaban and warfarin were 69.435, 69.219, 68.737 and 68.373 respectively. Estimated 
cost of treatment for dabigatran, warfarin, rivaroxaban and apixaban were 110,942 
USD, 108,757 USD, 124,718 USD and 112,373 USD, respectively. ICER showed that 
dabigatran is a cost-saving alternative versus rivaroxaban and apixaban, and a 
cost-effective one versus warfarin (defined by a one GDP per capita threshold in the 
country). These results where robust to changes in discount rates. ConClusions: 
From a perspective of Mexican public institutions, the treatment with dabigatran 
was found to be cost-effective when compared with warfarin and economically 
dominant versus rivaroxaban and apixaban as it resulted in highest projected life 
years gained at lower costs.
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objeCtives: Some high-risk CHD patients have poor outcomes with statin therapy 
and need to use combination regimens. The combination regimens have not been 
widely found in cost-effectiveness study. Therefore, this study aimed to analyze the 
cost-effectiveness of using Simvastatin, Atorvastatin, and Atorvastatin-Ezetimibe 
combination among high-risk CHD outpatients. Methods: A cross-sectional ret-
rospective study for 12 months (April 1, 2013 to April 1, 2014) in high-risk CHD out-
patients was performed at the Chandrubeksa Hospital Medical Department of the 
Royal Thai Air Force, Nakhon Pathom, Thailand. The incremental cost-effectiveness 
ratio (ICER) was determined for cost-effectiveness analysis. The direct medical costs 
were computed by micro-costing method (Reference price in 2014). The effective-
ness outcomes were the percentage differences in LDL-C reduction and the pro-
portion of patients achieving treatment goals (Standard goal (LDL-C < 100 mg/dL) 
and Aggressive goal (LDL-C < 70 mg/dL)). The cost-effectiveness was concerned on 
the provider perspective. Results: There were differences of the direct medical 
costs between three groups (median ± IQR: 517 ± 149.7, 3,910.4 ± 3,326.5, 13,733.7 
± 3,350.0; p 0.0001, respectively). Simvastatin regimen had the lowest percentage 
differences in LDL-C reduction when compared to other groups (mean ± SD ; -20.1 
± 30.1, -28.3 ± 24.2, -38.1 ± 17.1; p 0.0001, respectively). Atorvastatin regimen provide 
the best cost-effectiveness (ICER = 346.4 THB) by using the proportion achieved 
standard treatment goal, while Atorvastatin-Ezetimibe combination was dominated. 
In the case of the aggressive treatment goal showed that Atorvastatin-Ezetimibe 
combination regimens provided the most cost-effectiveness (ICER 437.7 THB and 
1,189.8 THB, respectively). ConClusions: Comparison treatment with Simvastatin, 
Atorvastatin and Atorvastatin-Ezetimibe combination among high-risk CHD out-
patients showed that Atorvastatin was more effectiveness and less costly than 
Atorvastatin-Ezetimibe combination in term of standard treatment goal. While 
Atorvastatin-Ezetimibe combination was an interesting option when aggressive 
treatment goal was used.
PCV68
CloPiDogrEl VErsus asPirin in PatiEnts with athErothroMbosis: 
a CaPriE-basED EConoMiC analysis in a hEalth rEsourCE liMitED 
sEtting
Li T.1, Liu M.B.2, Ben H.3, Xu Z.X.4, Zhong H.5, Wu B.5
1Department of Pharmacy, Yuxi People’s Hospital, Yuxi, China, 2Department of Pharmacy, Fujian 
Union Hospital, Fujian, China, 3Department of Cardiology, Ren Ji Hospital, Shanghai, China, 
4Department of Cardiology, Gongli Hospital, Shanghai, China, 5Department of General Surgery, 
Ren Ji Hospital, Shanghai, China
